CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79.75% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Veracyte’s Decipher Test Predicts Abiraterone Benefit in Very High-Risk Prostate Cancer Study

By Public Technologies
  • Veracyte’s Decipher Prostate test predicted benefit from adding abiraterone to hormone therapy in men with very high-risk, nonmetastatic prostate cancer.
  • The retrospective analysis of the Phase III STAMPEDE trial included 401 patients; higher Decipher scores identified greater benefit in reducing cancer spread.
  • Findings support using the test before treatment intensification to weigh potential benefits against abiraterone’s added side effects and treatment burden.
  • Results will be presented at the European Society for Medical Oncology Congress on October 24, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veracyte Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610230400PRIMZONEFULLFEED9851884) on October 23, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.